ImmunityBio, Inc.
IBRX
$2.51
$0.041.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 30.99% | 36.29% | -0.34% | 42.54% | -144.18% |
| Total Depreciation and Amortization | -7.12% | 1.11% | -3.27% | -0.20% | -0.46% |
| Total Amortization of Deferred Charges | -19.23% | 6.29% | 5.10% | -22.04% | -37.86% |
| Total Other Non-Cash Items | -78.07% | -173.26% | -11.00% | -84.18% | 15,524.50% |
| Change in Net Operating Assets | -7.88% | -287.40% | 237.76% | 84.88% | -267.69% |
| Cash from Operations | 13.79% | 1.58% | 6.20% | 7.19% | -31.88% |
| Capital Expenditure | 24.39% | -285.64% | 42.59% | 84.15% | -40.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -82.39% | 233.60% | -47.74% | -436.74% | 202.49% |
| Cash from Investing | -84.88% | 226.30% | -44.55% | -1,683.90% | 114.39% |
| Total Debt Issued | -100.00% | -- | -- | -- | -3.13% |
| Total Debt Repaid | 100.00% | -4.76% | 0.00% | -5.00% | -5.26% |
| Issuance of Common Stock | 577.43% | -69.68% | 271.58% | 50.86% | -76.60% |
| Repurchase of Common Stock | -168.56% | 39.72% | 87.17% | -147.57% | -6.69% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -200.00% | 3,232,066.67% | -- | -- |
| Cash from Financing | 586.23% | -89.53% | 1,356.18% | -94.90% | -15.56% |
| Foreign Exchange rate Adjustments | -163.64% | -8.33% | 130.77% | -44.44% | -2,600.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 274.29% | -518.83% | 97.79% | -251.35% | -34.94% |